Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Antiviral Res. 2019 Apr 7;167:25–34. doi: 10.1016/j.antiviral.2019.04.004

Figure 2. Prophylactic efficacy of BDGR-4 administered for 5 days in C3H/HeN mice challenged with intranasal VEEV TC-83.

Figure 2.

Groups of six C3H/HeN mice per treatment, vehicle, BDGR-4 at 1, 5 or 25 mg/kg/day, were assessed for (A) survival and (B) morbidity over 21 days following an i.n. challenge with VEEV TC-83. (C) Brains (n = 4) were taken for VEEV TC-83 titer by TCID50 on day 4. (D) Treatments were administered i.p. in a volume of 0.1 ml in 25%PEG400/10%RH40/65%water starting at 2 hours prior to virus infection (D0) and were given BID for 5 days (D0-D4).